Covid-19 roundup: Roche's Actemra marred by negative results; Here comes another single-armed remdesivir trial
Despite initial promising signs, Roche’s Actemra appears unable to escape the fate of Sanofi and Regeneron’s IL-6 Kevzara, as it failed to reduce severe respiratory symptoms, intensive care visits, or death any better than standard treatments of Covid-19.
Investigators in Italy stopped the trial early after reaching the conclusion at an interim analysis. They had enrolled only 126 patients, about one third of the intended number.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.